Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN5 | P54829 | 1/20 | 0.46 |
| ▸ | UQCRB | P14927 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 6/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547561 | 0.90 | UQCRB (0.43) | PTPN5UQCRBMEN1KMT2AALDH1A1 | |
| SCHEMBL2749970 | 0.89 | MEN1 (0.48) | PTPN5UQCRBMEN1KMT2AALDH1A1 | |
| SCHEMBL2748545 | 0.84 | HSD17B2 (0.53) | PTPN5UQCRBMEN1KMT2AALDH1A1 | |
| SCHEMBL27703446 | 0.77 | PTPN5 (0.56) | PTPN5UQCRBMEN1KMT2AALDH1A1 | |
| SCHEMBL3984770 | 0.74 | SERPINE1 (0.58) | PTPN5UQCRBMEN1KMT2AALDH1A1 | |
| SCHEMBL1094560 | 0.74 | PTPN5 (0.57) | PTPN5UQCRBHSD17B2KDM4E | |
| SCHEMBL2748031 | 0.73 | UQCRB (0.53) | PTPN5UQCRBALDH1A1HSD17B2KDM4E | |
| SCHEMBL2748358 | 0.73 | KDM4E (0.52) | UQCRBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL2747439 | 0.69 | ACLY (0.60) | PTPN5UQCRBMEN1KMT2AALDH1A1 | |
| SCHEMBL2250816 | 0.68 | NPSR1 (0.67) | UQCRBHSD17B2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | claimed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178699-B2 | Modulators of CCR9 receptor and methods of use thereof | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2220065-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017719-A2 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029753-A1 | MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | PTPN5 951/4885UQCRB 4425/4885MEN1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.